Agile_Logo-color on white.jpg
Agile Therapeutics Completes Pay-off of Debt and Remains Focused on Business Plan Execution
March 13, 2024 07:31 ET | Agile Therapeutics, Inc.
PRINCETON, N.J., March 13, 2024 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX) (“Agile” or the “Company”), a women's healthcare company, today announced that it has paid-off the...
Agile_Logo-color on white.jpg
Agile Therapeutics Announces Exercise of Warrants for $4.8 Million Gross Proceeds
February 22, 2024 09:01 ET | Agile Therapeutics, Inc.
PRINCETON, N.J., Feb. 22, 2024 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX) (“Agile Therapeutics” or the “Company”), a women's healthcare company, today announced the entry into a...
Agile_Logo-color on white.jpg
Agile Therapeutics Announces Extension Granted by Nasdaq Hearings Panel to Regain Compliance with the Stockholders’ Equity Continued Listing Requirement & Provides Performance Update
February 15, 2024 16:30 ET | Agile Therapeutics, Inc.
Company Granted Extension by Nasdaq Hearings Panel to Regain Compliance with the Stockholders’ Equity Continued Listing Requirement Until March 25, 2024 Net Revenue for Full Year 2023 Expected to be...
Agile_Logo-color on white.jpg
The Biden-Harris Administration Announces New Guidance to Enable Expanded Access to All FDA-Approved Contraceptives Without Cost
January 23, 2024 09:29 ET | Agile Therapeutics, Inc.
Implementation of the New Guidance Could Eliminate Financial Barriers for Contraceptive Products like Twirla® for 49 Million Women These Actions Follow Several Months of Activity by the Biden...
Agile_Logo-color on white.jpg
Agile Therapeutics Provides Update on Actions Being Taken to Strengthen the Affordable Care Act’s No-Cost Contraceptive Coverage Requirement
December 12, 2023 08:01 ET | Agile Therapeutics, Inc.
The Company Commends House Committee on Oversight and Accountability Ranking Member Jamie Raskin for New Report on Contraception Coverage Gaps New Report Follows Several Months of Activity by the...
Agile_Logo-color on white.jpg
Agile Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update
November 09, 2023 08:05 ET | Agile Therapeutics, Inc.
Twirla Delivers Third Quarter 2023 Net Revenue of $6.7 Million, a 21% Increase from Second Quarter 2023 Company Announces It Expects to Generate Positive Cash Flow from Operations in First Quarter...
Agile_Logo-color on white.jpg
Agile Therapeutics to Report Third Quarter 2023 Financial Results and Provide Business Update on Thursday, November 9, 2023
October 26, 2023 08:05 ET | Agile Therapeutics, Inc.
Live Conference Call and Webcast at 8:30 a.m. ET PRINCETON, N.J., Oct. 26, 2023 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, today announced it...
Agile_Logo-color on white.jpg
Agile Therapeutics Reports an Inducement Grant to New Chief Financial Officer Under Nasdaq Listing Rule 5635(c)(4)
October 04, 2023 16:30 ET | Agile Therapeutics, Inc.
PRINCETON, N.J., Oct. 04, 2023 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women’s healthcare company, today announced the granting of a previously disclosed inducement award to...
Agile_Logo-color on white.jpg
Agile Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment Conference
September 05, 2023 08:05 ET | Agile Therapeutics, Inc.
PRINCETON, N.J., Sept. 05, 2023 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, today announced that Chairperson and Chief Executive Officer Al Altomari...
Agile_Logo-color on white.jpg
Agile Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update
August 09, 2023 08:05 ET | Agile Therapeutics, Inc.
Twirla Delivers Second Quarter 2023 Net Revenue of $5.5 Million, a 44% Increase from First Quarter 2023 Twirla Demand and Factory Sales Up 24% and 42% Respectively in Second Quarter 2023 Compared to...